Vivo Opportunity, LLC

CIK: 0001728970

Transaction Breakdown

Open Market Buys (P)30 (90.9%)

High conviction signal

Open Market Sales (S)3 (9.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

INM

InMed Pharmaceuticals Inc.

10% Owner

SLNO

SOLENO THERAPEUTICS INC

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (33 total)

INM
InMed Pharmaceuticals Inc.
Jul 16, 2026
Purchase(P)
Indirect
2 shares at avg. $1.55$3.1
INM
InMed Pharmaceuticals Inc.
Jul 16, 2026
Purchase(P)
Indirect
19 shares at avg. $1.55$29.45
INM
InMed Pharmaceuticals Inc.
Jul 15, 2026
Purchase(P)
Indirect
1.4K shares at avg. $1.55$2K
INM
InMed Pharmaceuticals Inc.
Jul 15, 2026
Purchase(P)
Indirect
13.8K shares at avg. $1.55$21K
INM
InMed Pharmaceuticals Inc.
Jul 14, 2026
Purchase(P)
Indirect
4.9K shares at avg. $1.55$8K
INM
InMed Pharmaceuticals Inc.
Jul 14, 2026
Purchase(P)
Indirect
493 shares at avg. $1.55$764.15
INM
InMed Pharmaceuticals Inc.
Jul 2, 2026
Purchase(P)
Indirect
1.5K shares at avg. $1.55$2K
INM
InMed Pharmaceuticals Inc.
Jul 2, 2026
Purchase(P)
Indirect
147 shares at avg. $1.55$227.85
INM
InMed Pharmaceuticals Inc.
Jul 1, 2026
Purchase(P)
Indirect
398 shares at avg. $1.55$616.9
INM
InMed Pharmaceuticals Inc.
Jul 1, 2026
Purchase(P)
Indirect
3.9K shares at avg. $1.55$6K
INM
InMed Pharmaceuticals Inc.
Jun 30, 2026
Purchase(P)
Indirect
55 shares at avg. $1.54$84.7
INM
InMed Pharmaceuticals Inc.
Jun 30, 2026
Purchase(P)
Indirect
545 shares at avg. $1.54$839.3
INM
InMed Pharmaceuticals Inc.
Jun 8, 2026
Purchase(P)
Indirect
29.5K shares at avg. $1.52$45K
INM
InMed Pharmaceuticals Inc.
Jun 8, 2026
Purchase(P)
Indirect
3K shares at avg. $1.52$5K
INM
InMed Pharmaceuticals Inc.
Jun 5, 2026
Purchase(P)
Indirect
50K shares at avg. $1.57$78K
INM
InMed Pharmaceuticals Inc.
Jun 5, 2026
Purchase(P)
Indirect
5K shares at avg. $1.57$8K
INM
InMed Pharmaceuticals Inc.
Jun 4, 2026
Purchase(P)
Indirect
618 shares at avg. $1.57$970.26
INM
InMed Pharmaceuticals Inc.
Jun 4, 2026
Purchase(P)
Indirect
6.1K shares at avg. $1.57$10K
INM
InMed Pharmaceuticals Inc.
Jun 3, 2026
Purchase(P)
Indirect
714 shares at avg. $1.55$1K
INM
InMed Pharmaceuticals Inc.
Jun 3, 2026
Purchase(P)
Indirect
7.1K shares at avg. $1.55$11K
INM
InMed Pharmaceuticals Inc.
Jun 2, 2026
Purchase(P)
Indirect
2.1K shares at avg. $1.52$3K
INM
InMed Pharmaceuticals Inc.
Jun 2, 2026
Purchase(P)
Indirect
20.8K shares at avg. $1.52$32K
INM
InMed Pharmaceuticals Inc.
Jun 1, 2026
Purchase(P)
Indirect
14.8K shares at avg. $1.55$23K
INM
InMed Pharmaceuticals Inc.
Jun 1, 2026
Purchase(P)
Indirect
1.5K shares at avg. $1.55$2K
INM
InMed Pharmaceuticals Inc.
May 29, 2026
Purchase(P)
Indirect
1.6K shares at avg. $1.57$3K

		Type	Shares	Price		Ownership
Jul 16, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	2	$1.55	$3	Indirect
Jul 16, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	19	$1.55	$29	Indirect
Jul 15, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	1,389	$1.55	$2,153	Indirect
Jul 15, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	13,761	$1.55	$21,330	Indirect
Jul 14, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	4,882	$1.55	$7,567	Indirect
Jul 14, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	493	$1.55	$764	Indirect
Jul 2, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	1,460	$1.55	$2,263	Indirect
Jul 2, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	147	$1.55	$228	Indirect
Jul 1, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	398	$1.55	$617	Indirect
Jul 1, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	3,946	$1.55	$6,116	Indirect
Jun 30, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	55	$1.54	$85	Indirect
Jun 30, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	545	$1.54	$839	Indirect
Jun 8, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	29,518	$1.52	$44,867	Indirect
Jun 8, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	2,982	$1.52	$4,533	Indirect
Jun 5, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	49,966	$1.57	$78,447	Indirect
Jun 5, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	5,045	$1.57	$7,921	Indirect
Jun 4, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	618	$1.57	$970	Indirect
Jun 4, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	6,125	$1.57	$9,616	Indirect
Jun 3, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	714	$1.55	$1,107	Indirect
Jun 3, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	7,069	$1.55	$10,957	Indirect
Jun 2, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	2,095	$1.52	$3,184	Indirect
Jun 2, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	20,753	$1.52	$31,545	Indirect
Jun 1, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	14,838	$1.55	$22,999	Indirect
Jun 1, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	1,498	$1.55	$2,322	Indirect
May 29, 2026	INM InMed Pharmaceuticals Inc.	Purchase(P)	1,632	$1.57	$2,562	Indirect

1-25 of 33 transactions

About Vivo Opportunity, LLC

Vivo Opportunity, LLC (SEC CIK 0001728970) files insider reports with the SEC as 10% Owner of InMed Pharmaceuticals Inc. (INM) and 10% Owner of SOLENO THERAPEUTICS INC (SLNO).

Signal8 holds 5 ownership filings by Vivo Opportunity, LLC (1 Form 3, 4 Form 4), filed between Mar 28, 2025 and Jul 16, 2026. Those filings report 33 transactions, from Mar 26, 2025 to Jul 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Vivo Opportunity, LLC's filings is in PALO ALTO, CA.

Recent filings by Vivo Opportunity, LLC

Jul 16, 2026: Open-market purchases of INM shares (2 lines, Form 4, code P).
Jul 15, 2026: Open-market purchases of INM shares (2 lines, Form 4, code P).
Jul 14, 2026: Open-market purchases of INM shares (2 lines, Form 4, code P).
Jul 2, 2026: Open-market purchases of INM shares (2 lines, Form 4, code P).
Jul 1, 2026: Open-market purchases of INM shares (2 lines, Form 4, code P).

Other insiders filing for InMed Pharmaceuticals Inc. (INM)

ADAR1 Capital Management, LLC, 10% Owner
Johnson Shane Aaron, Sr VP & General Manager
Lemerond Nicole, Director
Klompas Neil A, Director
Jagpal Netta, Chief Financial Officer
WOUDENBERG MICHAEL, Chief Operating Officer

How to read Form 4 transaction codes